N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND COMPOSITION CONTAINING SAME FOR TREATING DISORDERS OF CARDIOVASCULAR SYSTEM

Abstract: A N-substituted 3,4-dihydropyrimidine derivative of the formula (1): wherein R¹ is -(CH₂) n -X; X is substituted aminoethyl, substituted sulfideethyl, substituted or nonsubstituted heterocyclo-ethyl wherein the ethylene group is directly bonded to a hetero atom in the heterocyclic ring, or substituted or nonsubstituted heterocyclo-methyl wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring; n is an integer from 0 to 8; R² is straight, branched cyclic or cyclo-straight alkyl having from one to thirteen carbon atoms, or aralkyl having from seven to thirteen carbon atoms and pharmacologically acceptable acid additional salts thereof have substantially strong and long lasting effects. Therefore the compounds are useful as agents for treating disorders of the cardiovascular system, for example, antihypertensive agent, circulation improver and antianginal agent. A process for producing the above compounds econo­ mically and effectively is also disclosed.

Description: This invention relates to a N-substituted 3,4-dihydropyrimidine derivative of the formula (I): wherein R¹ is -(CH₂) n -X; wherein R³ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl, C₉₋₁₂ arylalkenyl, thienylmethyl or pyridylmethyl; R⁴ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl or C₉₋₁₂ arylalkenyl with the proviso that when one of R³ or R⁴ is said alkyl and the other is benzyl, said benzyl may be substituted with methoxy, nitro or halogen, or X is heterocyclo-ethyl wherein the ethylene group is directly bonded to the hetero atom in the heterocyclic ring, or heterocyclo-methyl wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring, said heterocyclic ring being pyrrolidinyl, piperidinyl, piperazinyl, morpholino, morpholinyl, thiomorpholinyl, thienyl, imidazolyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl, indolyl and thiobenzthiazolyl; and said piperazinyl being optionally substituted at the 4-position with methyl, ethyl, propyl, phenyl, benzyl, benzhydryl, acetyl, propionyl, benzoyl, cinnamoyl, n is an integer from 0 to 8; the nitro substituent is in the ortho- or meta-position of the phenyl ring; R² is C₁₋₁₃ straight alkyl, up to C₁₃ branched or cyclic alkyl, or up to C₁₃ cyclo-straight alkyl; or when the nitro substituent is in the ortho position R¹ is 2-[4-(3,4,5-trimethoxycinnamoyl)-1-piperazinyl] ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3-trifluoromethylphenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-chlorobenzhydryl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(9-fluorenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-benzyloxy-benzyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or a pharmacologically acceptable acid addition salt thereof, a process for production thereof, a pharmaceutical composition comprising said compound and an agent for treating disorders of the cardiovascular system. Since the above dihydropyrimidine derivatives of the formula (1) have a strong and long lasting vasodilative effect, said compounds are useful as agents for treating disorders of the cardiovascular system, for example, antihypertensive agent, cerebral circulation improver and antianginal agent. Currently it has been found that calcium antagonists (Ca⁺⁺ antagonists), which had been spotlighted as new agents for treating disorders of the cardiovascular system, have a variety of pharmacological effects and are active not only against hypertension, angina pectoris, cerebral circulation disorder and arrhythmia but also in preventing arteriosclerosis and potentiating the effects of carcinostatic agents. Thus therapeutic uses of Ca⁺⁺ antagonists continue to increases. Ca⁺⁺ antagonists which have been known include Nifedipine, Nicardipine, Verapamil, Diltiazem and the like. Up to this day, however, dihydropyrimidine derivatives have not often been investigated. Only a few references disclose said derivatives. [For example refer to Silversmith, E.F.J., Org. Chem., 27, 4090 (1962), Nasipuri, D. et al., Synthesis 1073 (1982), Kashima, C., Tetrahedron Letters 209 (1983) and Japanese Patent Public Disclosure No. 73572/59 (Bayer, A.G.)] This can be considered to be due to the instability and tautomerism of the dihydropyrimidine derivatives. But there is room for improvement in the properties of the above-mentioned Ca⁺⁺ antagonists such as duration of action, organ-selectivity, stability against light, heat etc. and with respect to side effects. EP-A-0 103 796 refers to dihydropyrimidines, a process for preparing them and their use in drugs. The dihydropyrimidine compounds of said prior art do not have a ROOC group being bonded to nitrogen atom in the pyrimidine ring and are therefore different in structure. EP-A-0 161 877 refers to 1,4-dihydropyridine derivatives, methods for their production and pharmaceutical compositions comprising the same. The 1,4-dihydropyridine derivatives of said prior art have the disadvantage of light-lability. EP-A 0 162 208 discloses N-substituted 3,4-dihydropyrimidine derivatives and pharmaceutical compositions. Said N-substituted 3,4-dihydropyrimidine derivatives differ from the compounds of the present invention by their substituents. Pharmacological comparative data relating to vascular resistance activity (ED₃₀) indicate that the inventive compounds are superior to the prior art compounds. The inventors thoroughly investigated the Ca⁺⁺ antagonists which are currently considered to be important. As a result we found that N-substituted 3,4-dihydropyrimidine derivatives have excellent vasodilative effects and high stability. (Refer to Japanese Patent Public Disclosure No. 214778/85, 246376/85, and 252471/85 and 43171/86.) However, the inventors more eagerly investigated the Ca⁺⁺ antagonists which have the most excellent vasodilative effects and stability over a long term and reduced toxicity levels. As a result we have found that the N-substituted-3,4-dihydropyrimidine derivatives of the formula (1) not only have excellent stability and strong vasodilative effects but also long-term duration. The present invention provides N-substituted 3,4-dihydropyrimidine derivatives of the formula (1) and pharmaceutically acceptable acid addition salts thereof. wherein R¹ and R² are as defined above. Dihydropyrimidine derivatives of the formula: wherein R² is as defined above, and which are tautomeric isomers, have vasodilative effects too. But the compounds of the formula (1) were synthesized in order to obtain compounds having higher stability and pharmacological activity. N-substituted 3,4-dihydropyrimidine derivatives of the formula (1) can be prepared in the following procedures: (i) Tautomeric isomers of the formula (2) and (2'): wherein R² is as defined above may be prepared by the following method: A compound of the formula R²OH wherein R² is as defined above is heated with one equivalent amount of diketene at 100°C - 200°C, preferably 120°C for 30 - 60 minutes to give β-ketoester of the formula (3): wherein R² is as defined above. Alternatively, a compound of the formula (3) can be obtained by treating a compound of the formula R²OH in the presence of an equivalent amount of a base such as trialkylamine at room temperature or treating said compound with said diketene at 0°C, or reacting said compound with diketene in the presence of sodium hydride or potassium hydride. Benzaldehyde wherein the benzene ring is substituted with nitro group is added to the β-ketoester (3) and the mixture is subjected to dehydration-condensation to produce a benzylidene compound of the formula (4) wherein R² is as defined above. The benzylidene (4) is condensated with acetamidine or acetamidine hydrochloride to produce a tetrahydropyrimidine compound (5) of the formula: In order to obtain the compound (5), the above condensation above is carried out in the presence of a base. Preferable bases for use in this procedure include metal alkoxides and metal hydride and suitable solvents include alcohols, ethers and dimethylformamide. The tetrahydropyrimidine (5) is heated in the presence of a catalyst such as p-toluenesulfonic acid, boron trifluoride or camphor-sulfonic acid, or heated with silicagel, alumina or molecular sieves to produce compounds represented by the formulae (2) and (2'). The thus obtained compounds may be purified by a conventional purification method such as adsorption chromatography, ion-exchange chromatography, partition chromatography, distillation or recrystallization. Alternatively, the dihydropyrimidine derivatives of the formulae (2) and(2') may be crystallized as salts with an inorganic acid such as hydrochloric acid, sulfuric acid or phosphoric acid, or an organic acid such as oxalic acid, tartaric acid, succinic acid or maleic acid and may be purified by recrystallization. (ii) Preparation of N-substituted 3,4-dihydropyrimidine derivatives: The compound represented by the formulae (2) and (2') obtained in the above (i) is dissolved in an organic solvent such as hydrocarbon chlorides, aromatic hydrocarbons or ethers and the solution is added to a solution of phosgene or phosgene dimer in an organic solvent at a temperature not higher than 0°C, preferably -10 ∼ -35°C in the presence of a base, for example, trialkylamine, preferably triethylamine, sodium hydride or potassium hydride. After the reaction is completed, a solution of a nitrogen-containing alcohol compound of the formula R¹OH wherein R¹ is as defined above is further added to the reaction to afford the compound of the formula (1). The reaction mixture is treated with said alcohol in the presence of or in the absence of a base at from 0°C to room temperature. The organic solvents used in this procedure include any solvents which do not affect the reaction, preferably ethers and hydrocarbon chlorides. The substituent R² at the position 5 of the N-substituted 3,4-dihydropyrimidine derivative (1) can be exemplified by C₁₋₁₃ straight alkyl, C₃₋₁₃ branched or cyclic alkyl or C₄₋₁₃ cyclo-straight alkyl. The substituent R¹ of the ester residue at the position 3 of said derivative is represented by the formula -(CH₂) n -X wherein n is an integer from 0 to 8. When X is R₃ is exemplified by methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, phenyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl, naphthylethyl, cinnamyl, cinnamylmethyl, pyridylmethyl or thienylmethyl and R⁴ is exemplified by methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, phenyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl, naphthylethyl, cinnamyl and cinnamylmethyl with the proviso that when one of R³ or R⁴ is said alkyl and the other is benzyl, said benzyl may be substituted with methoxy, nitro or halogen. When X is heterocyclo-ethyl, wherein the ethylene group is directly bonded to the hetero atom in the heterocyclic ring, or heterocyclo-methyl, wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring, the heterocyclic ring is exemplified by pyrrolidinyl, piperidinyl, piperazinyl, morpholino, morpholinyl, thiomorpholinyl, thienyl, imidazolyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl or indolyl and thiobenzthiazolyl and may be mono-substituted with alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl or acyl. The phenyl ring of the above mono-substituent may be substituted with nitro, iodo, chloro, dichloro, bromo, dibromo, fluoro, methoxy, dimethoxy, trimethoxy, trifluoromethyl, cyano or thiomethyl. Among the above-mentioned substituted piperazinyl groups, piperazinyl substituted at position 4 such as 4-benzylpiperazinyl, 4-benzhydrylpiperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-propyl-piperazinyl, 4-acetylpiperazinyl, 4-propionylpiperazinyl, 4-benzoylpiperazinyl, 4-cinnamoylpiperazinyl or 4-phenylpiperazinyl is suitable. After the above reaction the products of the formula (1) of this invention can be purified by using conventional methods such as adsorption column chromatography, ion-exchange chromatography or recrystallization. Alternatively, the products can be treated with an inorganic acid such as hydrochloric acid, sulfuric acid or phosphoric acid, or an organic acid such as oxalic acid, succinic acid or malic acid to convert them to salts thereof, and then can be purified by recrystallization, adsorption chromatography or ion-exchange chromatography. The thus obtained compounds of the formula (1), when administered intra arterially (i.a.) or intravenously (i.v.) and orally (p.o.), indicated a strong coronery vasodilative effect in isolated guinea pig hearts (Langendorff's method) (i.a.), and showed strong cerebral vasodilative and hypotensive effects in anesthetized dogs (i.v.), and in conscious spontaneously hypertensive rats (p.o.). And all of these effects are superior to known drugs such as Nicardipine in terms of potency and duration. Thus, the compounds are considered to be useful as agents for treating angina pectoris (myocardial infarction), disturbance of cerebral circulation and hypertension. The compounds (1) of this invention can be administered alone or in combination with excipients in a variety of dosage forms such as tablets, troches, pills, granules, powders, capsules, ampules, suppositories and the like. The excipients include, for example, starch, dextrin, sucrose, lactose, silicic acid, carboxymethylcellulose, cellulose, geratin, polyvinylpyrrolidone, glycerin, agar, calcium carbonate, sodium bicarbonate, paraffin, cetyl alcohol, stearic acid esters, kaolin, bentonite, talc, calcium stearate, magnecium stearate, polyethyleneglycol, water, ethanol, isopropylalcohol, propyleneglycol and the like. For parenteral administration, the compounds of this invention are converted into water soluble salts thereof and the salts are dissolved in sterile distilled water or sterile physiological saline and are filled in ampules to be used for injection. If necessary, stabilizing agents and/or buffering agents can be included in the ampules. For oral administration, the optimum dose range of the compound (1) of this invention is 5 - 500 mg per day. Of course, this dose range can be suitably changed depending upon the characteristics of the subjects including age, response, body weight, severity of disease etc. This invention can be illustrated by the following examples but it should be understood that it is not limited to them. The temperatures stated are in °C unless otherwise specified. Example 1 3-{2-(N-benzyl-N-methylamino)ethoxycarbonyl}-5-cyclopropylmethoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3,4-dihydropyrimidine (1): Trichloromethyl chloroformate (144 µl) was dissolved in 10 ml of tetrahydrofuran (THF). To the resulting solution, a mixture of 5-cyclo-propylmethoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyrimidine (329 mg) and triethylamine (607 ml) in THF (20 ml) was added under stirring at -23°C, followed by stirring for an additional one hour. To the resulting mixture, 2-(N-benzyl-N-methyl-amino)ethan-1-ol (991 mg) in THF (10 ml) was added at 0°C, followed by stirring for one hour. The stirring was continued for one more hour at room temperature and, thereafter, the reaction mixture was diluted with a saturated aqueous solution of sodium chloride and subjected to extraction with chloroform. After drying the extract, the solvent was evaporated and the residue (1.32 g) was subjected to silica gel chromatography. By elution with 1% methanol-chloroform, the desired compound was obtained in an amount of 354 mg (yield: 68%). The physicochemical data of the compound are shown in Table 1. The procedures of Example 1 were repeated in Examples 2 - 27 and the resulting compounds had the physicochemical data shown in Table 1. Example 28 3-[2-{N-benzyl-N-(3-phenylpropyl)amino}ethoxycarbonyl]-5-cyclopropylmethoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3,4-dihydropyrimidine (1): Method 1 : Trichloromethyl chloroformate (719 µl) was dissolved in 40 ml of tetrahydrofuran (THF). To the resulting solution, a mixture of 5-cyclopropylmethoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyrimidine (1.65 g) and triethylamine (3.04 g) in THF (80 ml) was added under stirring at -23°C, followed by stirring for an additional one hour at -23°C. To the resulting mixture, 2-{N-benzyl-N-(3-phenylpropyl)amino}ethan-1-ol (6.73 g) in THF (40 ml) was added at 0°C, followed by stirring for 2 hours at room temperature. The reaction mixture was diluted with a saturated aqueous solution of sodium chloride and subjected to extraction with chloroform. After drying the extract, the solvent was evaporated and the residue (ca. 12 g) was subjected to silica gel chromatography. By elution with a 1:1 mixture of ethyl acetate and n-hexane, the end compound was obtained in an amount of 2.14 g (yield: 69%). Method 2 : Trichloromethyl chloroformate (300 µl) was dissolved in 30 ml of tetrahydrofuran (THF). To the resulting solution, a mixture of 5-cyclopropylmethoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyrimidine (1.65 g) and triethylamine (3.04 g) in THF (70 ml) was added under stirring at -23°C, followed by stirring for an additional one hour at -23°C. To the resulting mixture, 2-{N-benzyl-N-(3-phenylpropyl)amino}ethan-1-ol (1.35 g) in THF (50 ml) was added at 0°C, followed by stirring for 2 hours at room temperature. The reaction mixture was diluted with a saturated aqueous solution of sodium chloride and subjected to extraction with chloroform. After drying the extract, the solvent was evaporated and the residue (ca. 4.6 g) was subjected to silica gel chromatography. By elution with a 1:2 mixture of ethyl acetate and n-hexane, the end compound was obtained in an amount of 1.51 g (yield: 48%). The physical data of the end compound are shown in Table 2. The procedures of method 1 and 2 were repeated in Examples 29 - 74. The data of the compounds prepared in Examples 29 - 74 are also listed in Table 2. Example 75 The coronary vascular dilative effect of 3N-substituted 3,4-dihydropyrimidine derivatives was tested. Test method Heartley guinea pigs (weight 400 - 500 g) were killed by a flow on the head and their hearts were immediately isolated. The hearts were perfused with Krebs-Henseleit solution bubbled with a mixture of 95% O₂ + 5% CO₂ and maintained at 37°C at a constant rate of 6 ml/minute according to the Langendorff's method [J. Pharmacol. Methods 2 , 143 (1979)]. The perfusion pressure was measured by a pressure transducer continuously. Samples were prepared by emulsifying 1 mg of a test compound in 1 ml of a mixture of dimethylsulfoxide and physiological saline solution (1:9) and diluting with physiological saline solution to the predetermined concentration. 0.1 ml of the diluted solution was administered into the coronary artery via a rubber tube connected to an aorta cannula to obtain ED₅₀ (µg/heart) data as shown in Table 3. The numbers of the compounds in the Table correspond respectively to those of the working examples described above. Example 76 The pharmacological effect (ED₃₀) of the compounds of the present invention with respect to the vascular resistance of the vertebral artery in anesthetized dogs was tested by the following procedure. Test method Adult dogs of either sex (7 - 14 kg in body weight) were anesthetized with at first thiopental sodium (35 mg/kg, intraperitoneal), anesthetized with urethane (400 mg/kg, intravenous) and chloralose (60 mg/kg, intravenous) and kept under artificial respiration throughout the experiment. After thoracotomy at the left first intercostal space, the vertebral artery was exposed and blood flow was measured with intracorporeal flow probe connected to an electromagnetic flowmeter (MF-27, Nihon Kohden). At the same time, continuous measurement of the following parameters was made: systemic blood pressure (mean pressure) at the right femoral artery, the limb lead II ECG, the heart rate with a tachometer triggered by the R wave of ECG, and the vascular resistance determined by loading a electronic divider unit (EO-601 G, Nihon Kohden) with the mean values of blood pressure and vertebral artery blood flow. All of these parameters were recorded simultaneously on a polygraph (RM-600, Nihon Kohden). All the test compounds were injected through a cannula inserted into the femoral vein. The ED₃₀ (µg/kg) values obtained by intravenous injection are listed in Table 4, wherein the Compound Numbers are keyed to the Example Numbers. Compound (Ex. No.) 1 2 3 5 6 7 8 ED₃₀ (µg/kg) 0.58 0.84 0.75 2.4 1.4 0.71 4.1 9 10 11 14 15 16 17 19 3.9 0.54 0.55 2.1 2.5 3.8 3.4 1.4 20 21 26 28 29 30 32 35 4.0 2.0 4.1 4.2 2.5 0.60 3.2 4.2 38 39 40 45 46 48 49 50 4.2 2.3 1.5 1.8 2.0 2.0 2.8 0.74 52 53 54 55 57 58 60 61 1.5 2.5 1.4 3.8 0.48 2.5 1.7 1.4 62 63 64 67 68 70 71 1.2 1.3 0.93 1.0 4.4 3.0 5.0 Example 77 Selected compounds of the present invention were tested for their ability to reduce the resistance of the vertebral artery in anesthetized dogs. Test method : The animals were injected with the ED₃₀ doses of test compounds and the time course of changes in the vasucular resistance were studied as shown schematically in Fig. 1. From the curve shown in Fig. 1, the values of T 1/2 (min) (the time to reach 50% of the resistance drop). The results are shown in Table 5, in which the compound numbers correspond to the Example numbers. Example 78 A selected compound of the present invention was tested for its hypotensive action in conscious spontaneously hypertensive rats (SHR). Test method : A group of 17 to 20-week old male SHR were anesthetized with ether and a cannula was inserted into the left femoral artery. At least one day after the operation, the cannula was connected to a pressure transducer and the blood pressure was measured continuously under conscious and unrestrained condition, thereby obtaining the data shown in Table 6. The test compound as clear solution dissolved in 10% ethanol was administered orally at a dose of 10 mg/kg (body weight) to each animal fasted overnight. Compound No. Blood pressure decrease (%) maximum decrease 6 hours 28 in 2 hrs. 35% 10 - 20% Example 79 The acute toxicity (LD₅₀) data of compound No. 28 of the present invention as administered to two groups of 5 or 6-week old male ddY mice were obtained by the Litchfield-Wilcoxon method. The results are shown in Table 7. One group of mice was fasted overnight prior to oral administration. To each group of mice, the test compound was administered in the form of emulsion in 10% dimethyl sulfoxide. Compound No. LD₅₀ (mg/kg) intravenous oral 28 180 - 200 >1,000 The compounds of this invention have a strong and long-lasting vasodilative effect. Therefore said compounds are considered to be useful as agents for treating disorders of the cardiovascular system such as angina pectoris, arrhythmia, hypertension or disturbance of cerebral circulation. Such disorders can be treated by administering the compound of the present invention, at a low dose level and at infrequent interval. This will make sure that treatment of such disorders can be done safely and easily.

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A N-substituted 3,4-dihydropyrimidine derivative of the formula (I): wherein R¹ is -(CH₂) n -X; wherein R³ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl, C₉₋₁₂ arylalkenyl, thienylmethyl or pyridylmethyl; R⁴ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl or C₉₋₁₂ arylalkenyl with the proviso that when one of R³ or R⁴ is said alkyl and the other is benzyl, said benzyl may be substituted with methoxy, nitro or halogen, or X is heterocyclo-ethyl wherein the ethylene group is directly bonded to the hetero atom in the heterocyclic ring, or heterocyclo-methyl wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring, said heterocyclic ring being pyrrolidinyl, piperidinyl, piperazinyl, morpholino, morpholinyl, thiomorpholinyl, thienyl, imidazolyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl, indolyl and thiobenzthiazolyl; and said piperazinyl being optionally substituted at the 4-position with methyl, ethyl, propyl, phenyl, benzyl, benzhydryl, acetyl, propionyl, benzoyl, cinnamoyl; n is an integer from 0 to 8; the nitro substituent is in the ortho- or meta-position of the phenyl ring; R² is C₁₋₁₃ straight alkyl, up to C₁₃ branched or cyclic alkyl, or up to C₁₃ cyclo-straight alkyl; or the nitro substituent is in the ortho position R¹ is 2-[4-(3,4,5-trimethoxycinnamoyl)-1-piperazinyl] ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3-trifluoromethylphenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-chlorobenzhydryl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(9-fluorenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-benzyloxy-benzyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or a pharmacologically acceptable acid addition salt thereof. A process for preparing a N-sbustituted 3,4-dihydropyrimidine derivative of formula (I) wherein the substituents R¹ and R² have the meaning as given in claim 1, as well as pharmacologically acceptable acid addition salt thereof, characterized by adding a dihydropyrimidine compound of the formula: wherein R² is as defined above, together with a base to a solution containing phosgene or phosgene dimer at a temperature not higher than 0°C, and treating the reaction mixture with an alcohol of the formula: R¹OH wherein R¹ is as defined above, in the presence of or in the absence of a base at from 0°C to room temperature. A process according to claim 2, wherein the base is trialkylamine. A pharmaceutical composition comprising a compound according to formula (I) of claim 1 and a pharmaceutically acceptable carrier. A composition for treating disorders of the cardiovascular system comprising a compound of formula (I) according to claim 1 and a pharmaceutically acceptable carrier. The use of a compound of formula (I) of claim 1 for the preparation of a pharmaceutical composition for treating disorders of the cardiovascular system. Claims for the following Contracting State : AT A process for preparing a N-sbustituted 3,4-dihydropyrimidine derivative of formula (I) wherein R¹ is -(CH₂) n -X; wherein R³ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl, C₉₋₁₂ arylalkenyl, thienylmethyl or pyridylmethyl; R⁴ is C₁₋₄ alkyl, benzyl, phenethyl, phenylpropyl, diphenylmethyl, naphthylmethyl or naphthylethyl, phenyl or C₉₋₁₂ arylalkenyl with the proviso that when one of R³ or R⁴ is said alkyl and the other is benzyl, said benzyl may be substituted with methoxy, nitro or halogen, or X is heterocyclo-ethyl wherein the ethylene group is directly bonded to the hetero atom in the heterocyclic ring, or heterocyclo-methyl wherein the methylene group is directly bonded to a carbon atom in the heterocyclic ring, said heterocyclic ring being pyrrolidinyl, piperidinyl, piperazinyl, morpholino, morpholinyl, thiomorpholinyl, thienyl, imidazolyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl indolyl and thiobenzthiazolyl; and said piperazinyl being optionally substituted at the 4-position with methyl, ethyl, propyl, phenyl, benzyl, benzhydryl, acetyl, propionyl, benzoyl, cinnamoyl; n is an integer from 0 to 8; the nitro substituent is in the ortho- or meta-position of the phenyl ring; R² is C₁₋₁₃ straight alkyl, up to C₁₃ branched or cyclic alkyl, or up to C₁₃ cyclo-straight alkyl; or when the nitro substituent is in the ortho position R¹ is 2-[4-(3,4,5-trimethoxycinnamoyl)-1-piperazinyl] ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3-trifluoromethylphenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-chlorobenzhydryl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(9-fluorenyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or R¹ is 2-[4-(4-benzyloxy-benzyl)-1-piperazinyl]ethyl group and R² is cyclopropylmethyl group; or a pharmacologically acceptable acid addition salt thereof, as well as pharmacologically acceptable acid addition salt thereof, characterized by adding a dihydropyrimidine compound of the formula: wherein R² is as defined above, together with a base to a solution containing phosgene or phosgene dimer at a temperature not higher than 0°C, and treating the reaction mixture with an alcohol of the formula: R¹OH Wherein R¹ is as defined above, in the presence of or in the absence of a base at from 0°C to room temperature. A process according to claim 1, wherein the base is trialkylamine. The use of a compound of formula (I) of claim 1 for the preparation of a pharmaceutical composition. The use of a compound of formula (I) of claim 1 for the preparation of a pharmaceutical composition for treating disorders of the cardiovascular system.

Inventors: CHO, HIDETSURA, MIZUNO, AKIRA, SHIMA, KEIYU
Applicants: SUNTORY LIMITED
Application year: 1986
Main classification: C07D239
IPC codes: A61K31, C07D239, A61P9, C07D409, C07D401, C07D417, A61P3, C07D403, C07D333